WuXi AppTec Sells China-Based Clinical Research Units to Hillhouse Investment Management

On October 25, 2025, WuXi AppTec announced the sale of its China-based contract research organization, WuXi Clinical, and its site management organization, WuXi MedKey, to Hillhouse Investment Management, a global asset manager15.

The sale is part of WuXi AppTec's plan to focus on its core contract research, development, and manufacturing organization (CRDMO) platform by divesting non-core clinical research businesses1.

Financial details of the transaction were not disclosed in the announcement1.

WuXi AppTec’s financial results for the first three quarters of 2025 showed an 18.6% year-over-year revenue increase, largely attributed to its CRDMO platform1.

This divestment follows WuXi's earlier sale of its U.S. medical device testing business, further sharpening its strategic focus1.

The company stated that this move is expected to enhance financial support for global development and growth of its core services1.

Sources:

1. https://www.fiercebiotech.com/cro/wuxi-apptec-sharpens-focus-selling-clinical-research-units

5. https://www.wsgr.com/en/insights/wilson-sonsini-advises-wuxi-apptec-on-sale-of-china-based-clinical-research-services-business-to-hillhouse.html